Shots:
- The P-III TANGO study evaluating the antiviral efficacy and safety of dolutegravir/lamivudine switching to a 2DR vs TAF based regimens in HIV-infected adults who had not experienced prior virologic failure
- The results showed that the 2-drug regimen demonstrated a non-inferior efficacy based on plasma HIV-1 RNA ≥50 c/mL @144wks. & resulted in no virologic failure compared to three drugs regimens in the ITT-E population, non-inferior virologic suppression (85.9% vs 81.7%) respectively, no resistance mutations were observed
- Additionally, no participants treated with dolutegravir/lamivudine met confirmed protocol-defined virologic failure @3yrs.
Click here to read full press release/ article | Ref: Businesswire | Image: Viiv Healthcare
The post ViiV Healthcare Presents Three-Year Results of Dovato (dolutegravir/lamivudine) in P-III TANGO Study for the Treatment of HIV at IDWeek 2021 first appeared on PharmaShots.
